Zusammenfassung
Donepezil (Donepezil Hydrochlorid) ist der zweite Acetylcholinesterase-Hemmer, der in Deutschland für die Behandlung von leichten und mittelschweren Demenzen vom Alzheimer-Typ zugelassen worden ist. Es handelt sich um einen Acetylcholinesterase-Hemmer vom Piperidin-Typ, der sich hinsichtlich seiner chemischen Struktur von anderen Cholinesterase-Hemmern wie Tacrin, einer Acridin-Verbindung oder Physostigmin, einem Carbamat, unterscheidet. Die Strukturformel ist der Abb. 12.3.1 zu entnehmen.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Galli A, Mori F, Benini L et al. (1994) Acetylcholinesterase protection and the anti-diisopropylfluorophosphate efficasy of E2020. Eur J Pharmacol Environ Toxicol Pharmacol 270: 189–193
Giacobini E, Zhu XD, Williams E, Sherman KA (1996) The effect of the selective reversible acetylcholinesterase inhibitor E2020 on extracellular acetylcholine and biogenic amine levels in rat cortex. Neuropharmacology 35: 205–211
Kawashima K, Sato A, Yoshizawa M et al. (1994) Effects of the centrally acting Cholinesterase inhibitors tetrahydroaminoacridine and E2020 on the basal concentration of extracellular acetylcholine in the hippocampus of freely moving rats. Naunyn Schmiedebergs Arch Pharmacol 350: 523–528
Kosasa T, Yamanishi Y, Ogura H et al. (1990) Effects of E2020 on the extracellular level of acethylcholine in the rat cerebral cortex measured by microdialysis without addition of Cholinesterase inhibitor [abstract]. Eur J Pharmacol 183: 1936
Mihara M, Ohnishi A, Tomono Y et al. (1993) Pharmacokinetics of E2020, a new compound for Alzheimer’s disease, in healthy male volunteers. Int J Clin Pharmacol Ther Toxicol 31(5): 223–229
Nochi S, Asakawa N, Sato T (1995) Kinetic study on the inhibition of acetylcholinesterase by 1-benzyl-4[85,6-dimethoxy-1-indanon)-2-yl] methylpiperidine hydrochloride (E2020). Biol Pharm Bull 18(8): 1145–1147
Ohnishi A, Mihara M, Kamakura H et al. (1993) Comparison of the pharmacokinetics of E2020, a new compound for Alzheimer’s disease, in healthy young and elderly subjects. J Clin Pharmacol 33: 1086–1091
Rogers SJ, Friedhoff LT (1997) The pharmacokinetic (PK) and pharmacodynamic (PD) profile of donepezil HCL (E2020) following single and multiple oral doses. Clin Pharmacol Ther 61(2): 181
Rogers SL, Friedhoff LT (1998) Long-term efficacy and safety of donepezil in the treatment of Alzheimer’s disease: an interim analysis of the results of a US multicentre open label extension study. Eur Neuropsychopharmacol 8: 67–75
Rogers SL, Yamanishi Y, Yamatsu K (1991) The pharmacology of a piperidine Cholinesterase inhibitor. In: Becker R, Giacobini E (eds) Cholinergic basis for Alzheimer therapy. Birkhäuser, Boston, pp 316–320
Rogers SL, Watters EJ, Friedhoff LT (1992) The pharmacokinetics (PK) and pharmacodynamics (PD) of E2020 [(R, S,)-1-benzyl-4-((5,6-dimethoxy-1-indanon)-2-yl)methylpiperadine hydrochloride), a novel inhibitor of acetylcholinesterase (AChE): implications for the use in treatment of Alzheimer’s disease. Neurobiol Aging 13 [Suppl 1]: 125–126
Rogers SL, Friedhoff LT et al. (1996a) The efficacy and safety of donepezil in patients with Alzheimer’s disease: results of a US multicentre, randomized, double-blind, placebo-controlled trial. The Donepezil Study Group. Dementia 7: 293–303
Rogers SL, Doody RS, Mohs RC, Friedhoff LT (1996b) Donepezil HCL (E2020) improves cognitive and global function in patients with mild to moderately severe Alzheimer’s disease: results of a 15-week phase III study. Poster, 35th Annual Meeting of the ACNP, pp 9–13
Rogers SL, Tiseo PJ, Friedhoff LT (1997) Pharmacokinetics of donepezil HCI (E2020) are unchanged in patients with impaired renal function. Clin Pharmacol Ther 61(2): 217 (PIII-91)
Rogers SL, Farlow MR, Mohs R, Friedhoff LT et al. (1998) A 24-week, doubleblind placebocontrolled trial of donepezil in patients with Alzheimer’s disease. Neurology 50: 136–145
Sherman KA (1991) Pharmacodynamics of oral E2020 and tacrine in humane: novel approaches. In: Becker R, Giacobini E (eds) Cholinergic basis for Alzheimer therapy. Birkhäuser, Boston, pp 321–328
Sugimoto H, Iimura Y, Yamanishi Y et al. (1992) Synthesis and anti-acetylcholinesterase activity of 1-benzyl-4-[(5,6-dimethoxy-l-indanon-2-yl)methyl]piperidine hydrochloride (E2020) and related compounds. Bioorg Med Chem Lett 2(8): 871–876
Sugimoto H, Iimura Y, Yamanishi Y, Yamatsu K (1995) Synthesis and structure-activity relationships of acetylcholinesterase inhibitors: 1-benzyl-4-[(5,6-dimethoxy-1-oxoindan-2yl) methyllpiperidine hydrochloride and related compounds. J Med Chem 38: 4821–4829
Tiseo PJ, Rogers SL, Friedhoff LT (1997a) The pharmacokinetic profile of donepezil HCl (E2020) in patients with impaired liver function. Clin Pharm Ther 61 (184): PII–P75
Tiseo PJ, Rogers SL, Friedhoff LT (1997b) Coadministration of donepezil HCL and digoxin produces no pharmacokinetic or pharmacodynamic interactions. Eur Neuropsychopharm 7 [Suppl 2] S252: P.4.024
Tiseo PJ, Rogers SL, Friedhoff LT (1997c) The pharmacokinetics and pharmacodynamics of (R)-and (S)-warfarin are uneffected by coadministration of donepezil HCL. Eur Neuropsychopharm 7 [Suppl 2]: 251 (P.4.023)
Yamanishi Y, Ogura H, Kosasa T, Araki S, Sawa Y, Yamatsu K (1990) Inhibitory action of donepezil, a novel acetylcholinesterase inhibitor, on Cholinesterase. Comparison with other inhibitors. In: Nagatsu T, Fisher A, Yoshida M (eds) Basic, clinical, and therapeutic aspects of Alzheimer’s and Parkinson’s diseases, vol 2. Plenum Press, New York, pp 409–413
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1999 Springer-Verlag Wien
About this chapter
Cite this chapter
Hegerl, U. (1999). Donepezil. In: Riederer, P., Laux, G., Pöldinger, W. (eds) Neuro-Psychopharmaka Ein Therapie-Handbuch. Springer, Vienna. https://doi.org/10.1007/978-3-7091-6400-6_66
Download citation
DOI: https://doi.org/10.1007/978-3-7091-6400-6_66
Publisher Name: Springer, Vienna
Print ISBN: 978-3-7091-7315-2
Online ISBN: 978-3-7091-6400-6
eBook Packages: Springer Book Archive